Clinical Trial of Sipjeondaebo-tang on Fatigue of Breast Cancer Patients

Sipjeondaebo-tang for Alleviating Fatigue Measured by Brief Fatigue Inventory and EORTC-QLQ-C30, BR23 Score Change Among Patients With Breast Carcinoma Receiving Chemotherapy

This is a pilot study that investigate efficacy and safety of Sipjeondaebo-tang on fatigue of patients with breast carcinoma receiving chemotherapy.

Inclusion Criteria:

• men and women aged over 18 years
• patients who have histologically or cytologically confirmed breast tumor
• patients who applicable AC(doxorubicin + cyclophosphamide)
• ECOG score 0 to 2

Exclusion Criteria:

• patient impossible to orally intake
• patient with dementia, delirium and depression
• patient suffering from diseases like chronic hepatitis B, C or hepatocirrhosis
• severe liver disability (3-fold the normal high range value for ALT, AST)
• patient who has diabetes not controlled by diet, hypertension, hyperthyroidism,
• severe systemic disease
• use of other investigational products within the past 30 days
• hypersensitivity to investigational product
• others who are judged not to be appropriate to study